Singapore

Key Insights

1
No psychedelic therapy is approved for routine patient access in Singapore; ketamine nasal spray was approved in October 2020 for severe depression, under tight control.
2
The database shows just 1 trial, 0 active, with ketamine and placebo as the only compounds studied, signalling a tiny, singular evidence base.
3
Singapore’s standout milestone is ketamine nasal spray approval in October 2020, making it one of the region’s earliest regulated depression-use cases.
4
Momentum is policy-led, not trial-led: MOH and HSA are tightening oversight of ketamine and other psychoactives, with no major public psychedelic research programme visible.

Medical Only (Private)

Reimbursed Care Access

Singapore maintains a highly restrictive statutory regime for classical psychedelics (psilocybin, MDMA, DMT, mescaline, 2C-X, 5‑MeO‑DMT, ibogaine, ayahuasca), classifying them as controlled substances under the Misuse of Drugs Act and enforced by the Central Narcotics Bureau (CNB). One exception in the therapeutic/regulated product space is esketamine (SPRAVATO®), which is registered by the Health Sciences Authority (HSA) for specific, specialist-administered indications; ketamine itself is a controlled drug but may be used under strict medical supervision in licensed settings. Reimbursement/coverage for esketamine and ketamine-based care is limited and depends on hospital/clinic policies and private insurance; there is no broad public scheme that expressly reimburses psychedelic-assisted therapies for Schedule I/Class A substances outside approved products or registered clinical trials.

Full guide →